Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9269MR)

This product GTTS-WQ9269MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9269MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15849MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ2773MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ13855MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ13478MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7500MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ12821MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ10384MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ7397MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW